Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
THL Credit Inc. 6.75% Notes du
TCRX | US
1.05
USD-0.01
-0.94%
TCRX | US
About THL Credit Inc. 6.75% Notes du
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
1.05
Open
1.06
High
1.09
Low
1.01
TScan Therapeutics Inc. a clinical-stage biopharmaceutical company develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200 TSC-201 TSC-202 TSC-203 and TSC-205 for the treatment of solid tumors. In addition it engages in the developing vaccines for infectious diseases such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research Inc. to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics Inc. was incorporated in 2018 and is headquartered in Waltham Massachusetts.
View LessTCRX | US
Risk
48.9
Sharpe
-0.18
Luna's Score
39/100
Recommendation
Sell
Luna says (TCRX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
58.2%1 month
48.9%3 months
59.6%6 months
89.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.11
Debt to equity
0.36
Debt to assets
0.24
Ent. to EBITDA
0.39
Ent. to rev.
6.38
PEG
-
Other Fundamentals
EBITDA
-106.66M
MarketCap
55.62M
MarketCap(USD)
55.62M
Div. yield
-
Op. margin
-6.36K
Erngs. growth
-
Rev. growth
-83.00
Ret. on equity
-46.84
Short ratio
9.15
Short perc.
5.40
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.23
Range1M
0.27
Range3M
0.37
Volumes: Market Activity
Rel. volume
1.72
Price X volume
1.17M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.39 | - | Cheaper |
| Ent. to Revenue | 6.38 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.11 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 59.65 | - | Par |
| Debt to Equity | 0.36 | -1.23 | Expensive |
| Debt to Assets | 0.24 | 0.25 | Par |
| Market Cap | 55.62M | - | Emerging |
